QuidelOrtho Co. (NASDAQ:QDEL) has been on the radar of investment firms for quite some time now. The latest Form 13F filing with the Securities & Exchange Commission reveals that Blair William & Co. IL has increased its stake in QuidelOrtho Co. by more than double during the 4th quarter of last year. The Illinois-based fund purchased an additional 21,325 shares, equivalent to an increase of 110.8%, bringing their total ownership to 40,568 shares worth a staggering $3,475,000.
This news comes as no surprise, given QuidelOrtho Co.’s rising position in the healthcare industry. With their innovative solutions and state-of-the-art technology for diagnostic testing and detection systems, the company has proven itself to be a reliable player in the field of healthcare diagnostics and bioscience research.
Blair William & Co.’s move to raise their stakes shows that they see vast potential in QuidelOrtho Co.’s future growth trajectory. As one of Chicago’s top management firms, Blair William & Co.’s expertise and knowledge make them a respected authority in the world of finance.
Furthermore, this latest development underscores QuidelOrtho Co.’s steadfast dedication to success and commitment to providing exceptional value to its shareholders in a highly competitive industry. By continuously introducing cutting-edge solutions that improve patient outcomes and transform medical practices globally, QuidelOrtho is well-positioned for long-term success.
In conclusion, Blair William & Co.’s increased stake in QuidelOrtho is not just a testament to the company’s impressive performance; it is also confirmation that investors recognize and appreciate excellence when they see it. With continued innovation and forward-thinking strategies from top industry players such as these two organizations working together collaboratively, there is no telling how high QuidelOrtho will go in its quest to drive the healthcare industry into a new age of better patient health outcomes and efficiency.
Institutional Investors Showing Confidence in QuidelOrtho Corp. with Strong Purchases
In recent months, QuidelOrtho Corp. (QDEL) has been the subject of much attention from investors and analysts alike, with many large investors modifying their holdings. Among them are Tredje AP fonden, Castleark Management LLC, Tocqueville Asset Management L.P., Pinebridge Investments L.P., and First Trust Advisors LP, all of whom have either purchased new positions in the company or increased their holdings.
Tredje AP fonden was one such investor who bought a new stake in QuidelOrtho during the fourth quarter of 2022. Their investment totaled approximately $548,000, indicating confidence in the future prospects of the company. Similarly, Castleark Management LLC purchased a new position worth around $3.37 million during the same period.
Tocqueville Asset Management L.P. raised its holdings in QuidelOrtho by 34.3% in the fourth quarter to now own 11,470 shares of the company’s stock valued at $983,000 after purchasing an additional 2,930 shares last quarter. Meanwhile, Pinebridge Investments L.P. lifted its position by 155.2% during this period as well.
Finally, First Trust Advisors LP lifted its position by 15.2% during Q4 and now owns over 400 thousand shares worth around $35 million.
These institutional investors account for approximately 95% of the stock currently owned in QuidelOrtho Corp., indicating positive sentiment towards its future direction.
QuidelOrtho Corp.’s performance has also recently been analyzed by research firms such as StockNews.com and Raymond James with price targets ranging from $130-$136 per share respectively.
Overall, while investing is always inherently risky and requires thorough due diligence on behalf of each investor or entity interested in diving into any financial endeavor – suggestions that Quidel Ortho could be a promising investment opportunity are coming through with a “moderate buy” rating and averaging at $123.83 by respected sources.
However, before considering an investment in QuidelOrtho, further research is warranted to ensure that the company aligns with your investment objectives and risk profile.
Discussion about this post